Shots:
- China’s NMPA has approved label expansion of sacituzumab tirumotecan (SKB264/MK-2870) to locally advanced or metastatic (LA/M) EGFRm NSCLC following disease progression on EGFR-TKI therapy or Pt-based Ct
- Approval was based on OptiTROP-Lung03 trial assessing sac-TMT alone (5mg/kg, IV, Q2W) vs docetaxel in mentioned pts, where it demonstrated improved ORR, PFS & OS
sac-TMT is fully deployed in NSCLC, with Merck & Kelun conducting 10 global & China-based P-III trials from late-line to early postoperative adj. settings, incl. a P-III (OptiTROP-Lung07) trial evaluating it in combination with osimertinib for 1L LA/M EGFRm NSCLC in China
Ref: Kelun-Biotech | Image: Kelun-Biotech
Related News:- The EC Approves BMS’ Opdivo + Yervoy as 1L Treatment for Hepatocellular Carcinoma
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
